← Human Trials & Peer-Reviewed Studies

The effects of a single-dose thermogenic supplement on resting metabolic rate and hemodynamic variables in healthy females--a randomized, double-blind, placebo-controlled, cross-over trial.

Plain-language guide to PMID 27034624 (2016): double-blind randomized controlled trial of Copper (Supplement) in 13 participants.

Key Facts

PMID
27034624
Journal
Journal of the International Society of Sports Nutrition
Year
2016
Study type
Randomized Controlled Trial
Authors
Campbell BI et al. (12 authors)
DOI
10.1186/s12970-016-0123-1

What This Study Did, in Plain Language

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

The purpose of this study was to examine the effects of a commercially available dietary supplement on RMR and hemodynamic variables in healthy females.

Why It Was Studied

Thermogenic dietary supplements can have a positive influence on RMR, but the magnitude can vary based on the active ingredient and/or combination of active ingredients.

Additionally, further safety evaluation is needed on multi-ingredient supplements that contain caffeine, due to its potential effect on heart rate (HR) and blood pressure (BP).

Who Took Part

The study group was 13 participants.

PubMed tags the participants as women only.

13 female participants (26.1 ± 11.3 years; 163.4 ± 9.1 cm; 63.7 ± 8.0 kg, and 24 ± 5 BMI) volunteered to participate in this investigation.

Participants underwent two testing sessions separated by approximately 7 days.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Copper (Supplement).

Some participants received a placebo instead of Copper (Supplement), giving a reference point.

In the crossover set-up each of the participants took both Copper (Supplement) and the comparison in turn, acting as their own control.

On their first visit, participants arrived to the laboratory after an overnight fast and underwent a baseline RMR, HR, and BP assessment.

Next, each participant ingested a thermogenic dietary supplement or placebo and repeated the RMR, HR, and BP assessments at 60, 120, and 180-minutes post-ingestion.

Approximately 1-week later, the alternative supplement was ingested and the assessments were repeated in the exact same manner.

Data were analyzed via a 2-factor [2x4] within-subjects repeated measures analysis of variance (ANOVA).

Post-hoc tests were analyzed via paired samples t-tests.

What Was Measured

Additionally, further safety evaluation is needed on multi-ingredient supplements that contain caffeine, due to its potential effect on heart rate (HR) and blood pressure (BP).

PubMed files the paper under topics including Analysis of Variance, Basal Metabolism, Calorimetry, Indirect, Dietary Supplements, Energy Metabolism, Heart Rate and Hemodynamics.

Author keywords: Fat loss, Female physique enhancement, Sports nutrition and Weight loss.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 13 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (Journal of the International Society of Sports Nutrition), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.

Our Notes on the Compound

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.